Successful Treatment With Single-Fraction Stereotactic Body Radiotherapy to Lung and Reirradiation of Neck Node Metastases in a Treated Base Tongue Primary

采用单次立体定向放射治疗成功治疗肺部转移灶,并对已治疗的舌根原发癌患者颈部淋巴结转移灶进行再次放射治疗。

阅读:1

Abstract

Introduction: Head and neck cancers are one of the most common cancers globally. Locoregional recurrence or distant metastasis is a common mode of recurrence and should be treated curatively, where feasible. We present a case of an elderly gentleman treated with reirradiation for nodal metastases and lung metastases ablated with single-fraction SBRT. Case Summary: An elderly 73-year-old gentleman treated with definitive radiotherapy 3 years ago for carcinoma of the base of the tongue presented with the complaint of left neck swelling for 3 weeks. A 2 × 3 cm left Level II lymph node was palpable with skin involvement. The positron emission tomography (PET) was suggestive of a left Level II cervical node measuring 4 × 4 × 3.2 cm, encasing the carotid artery and involving the skin, and a 3 × 2 cm right lower lobe lung lesion, suggestive of a metachronous lung primary or metastasis. The neck node was deemed unresectable due to more than 180-degree contact with vessels. The patient was unwilling to undergo a biopsy of the lung. Given the age, performance status and oligometastatic presentation, the patient was planned for radical intent treatment to both the neck node and the lung lesion. He was treated with reirradiation to the neck node with a dose of 66 Gy in 33 fractions over 6.5 weeks and SBRT 34 Gy in a single fraction to the lung lesion. He developed neck soft tissue necrosis, at 1.5 years after radiation, which resolved on antibiotics. The patient remains clinically well, and the PET scan performed at 1 and 2 years following radiation showed complete response with no new metastasis. Conclusion: Radical intent can be considered in oligometastatic head and neck cancers. Reirradiation is a treatment option for patients with recurrent head and neck cancers. Single-fraction SBRT is one of the recommended dose schedules for lung metastases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。